Wall Street analysts are busy modeling Eli Lilly's new weight-loss pill Foundayo as the next blockbuster drug. But there's a detail buried in the FDA label that could seriously limit who actually wants to take it - and nobody seems to be pricing it in.

Here's the issue: if you're a woman taking oral birth control, Foundayo requires you to either switch contraceptive methods or use backup protection for 30 days after starting the drug AND 30 days after each dose increase. Since it takes 3-6 months of dose escalations to reach the maximum effective dose, we're talking about half a year of condoms or switching off the pill entirely.

Novo Nordisk's oral version of Wegovy? No such restriction. They directly studied the interaction with oral contraceptives and found no clinically meaningful effect. Zero friction.

So what does this mean for you? If you're an investor, it means Lilly's "convenience" advantage might be a lot smaller than the company is suggesting. The whole pitch for the pill version was making weight-loss drugs more accessible to younger, less obese patients who don't want to deal with needles. But guess which demographic is most likely to be on birth control? That's right - younger women.

According to early prescription data from Reuters, Foundayo is pulling in about 20% of the weekly scripts that oral Wegovy managed in its first full week. That's... not great for a drug that's supposed to be the more convenient option.

One Wall Street analyst did the demographic math and estimates that 9-14% of Lilly's potential patient base could be affected by this birth control interaction once you account for the younger age profile of pill users versus injectable users. That's not a rounding error - that's a meaningful chunk of the addressable market.

And here's the kicker: Foundayo is also slightly less effective. In head-to-head trial comparisons, oral Wegovy showed about 14% weight loss at maximum dose versus 11% for Foundayo. So you're asking patients to accept lower efficacy AND potentially mess with their birth control. Not exactly a compelling value proposition.

For older, post-menopausal women or middle-aged men with metabolic syndrome - the traditional injectable GLP-1 market - this birth control thing doesn't matter. They've already demonstrated they don't care about friction; they signed up for needles and cold chain storage.

But if Lilly's growth story depends on expanding into a younger, more convenience-focused demographic, having your "convenience" option interfere with birth control is a problem. Especially when your competitor's version doesn't.

The catalyst to watch is Eli Lilly's Q1 earnings on April 30. If Novo's oral semaglutide is specifically winning the young female segment, this theory plays out over the next few quarters. And Wall Street might have to revise those blockbuster projections downward.

As I always say: if they're calling something "convenient" but ignoring obvious friction points, they're probably hiding something. Or in this case, burying it in the FDA label where nobody reads.